Download PDF
Dtsch Med Wochenschr 2012; 137(05): 210-213
DOI: 10.1055/s-0031-1292890
Verdauungs- und Stoffwechselkrankheiten | Commentary
Gastroenterologie, Onkologie
© Georg Thieme Verlag KG Stuttgart · New York

Hepatozelluläres Karzinom – Was ist neu?

Hepatocellular carcinoma: what‘s new?
A. Teufel
1   I. Medizinische Klinik und Poliklinik, Universitätsmedizin, Mainz
,
J. U. Marquardt
1   I. Medizinische Klinik und Poliklinik, Universitätsmedizin, Mainz
,
P. R. Galle
1   I. Medizinische Klinik und Poliklinik, Universitätsmedizin, Mainz
,
M. Wörns
1   I. Medizinische Klinik und Poliklinik, Universitätsmedizin, Mainz
› Author Affiliations
Further Information

Publication History

Publication Date:
16 January 2012 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

hepatozelluäres Karzinom - Sorafenib - mRECIST - transarterielle Chemoembolisation - Gensignatur

Keywords

hepatocellular carcinoma - sorafenib - mRECIST - transarterial chemoembolisation - genetic signature
 

  • Literatur

  • 1 Abou-Alfa GK, Amadori D, Santoro A et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest Cancer Res 2011; 4: 40-44
    PubMedSearch in Google Scholar
  • 2 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022
    CrossrefPubMedSearch in Google Scholar
  • 3 DuBray Jr BJ, Chapman WC, Anderson CD. Hepatocellular carcinoma: a review of the surgical approaches to management. Mo Med 2011; 108: 195-198
    PubMedSearch in Google Scholar
  • 4 Edeline J, Boucher E, Rolland Y et al. Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2011; Jun 28. [Epub ahead of print]
    PubMedSearch in Google Scholar
  • 5 Freise CE, Ferrell L, Liu T et al. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation 1999; 67: 510-513
    CrossrefPubMedSearch in Google Scholar
  • 6 Hojo M, Morimoto T, Maluccio M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-534
    CrossrefPubMedSearch in Google Scholar
  • 7 Hollebecque A, Cattan S, Romano O et al. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther 2011; 34: 1193-1201
    CrossrefPubMedSearch in Google Scholar
  • 8 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Liang W, Wang D, Ling X et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta-analysis. Liver Transpl 2011; Sep 30. [Epub ahead of print]
    PubMedSearch in Google Scholar
  • 10 Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
    CrossrefPubMedSearch in Google Scholar
  • 11 Maass T, Sfakianakis I, Staib F et al. Microarray-based gene expression analysis of hepatocellular carcinoma. Curr Genomics 2010; 11: 261-268
    CrossrefPubMedSearch in Google Scholar
  • 12 Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): An emerging field for advanced technologies. J Hepatol 2011; Jul 23. [Epub ahead of print]
    PubMedSearch in Google Scholar
  • 13 Marrero JA, Feng Z, Wang Y et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-118
    CrossrefPubMedSearch in Google Scholar
  • 14 Pawlik TM, Reyes DK, Cosgrove D et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011; 29: 3960-3967
    CrossrefPubMedSearch in Google Scholar
  • 15 Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2010; 30: 3-16
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin Liver Dis 2006; 26: 385-390
    Thieme ConnectPubMedSearch in Google Scholar
  • 17 Teufel A, Marquardt JU, Galle PR. Novel insights in the genetics of HCC recurrence and advances in transcriptomic data integration. J Hepatol 2011; Jul 23. [Epub ahead of print]
    PubMedSearch in Google Scholar
  • 18 Teufel A, Staib F, Kanzler S et al. Genetics of hepatocellular carcinoma. World J Gastroenterol 2007; 13: 2271-2282
    PubMedSearch in Google Scholar
  • 19 Toso C, Meeberg GA, Bigam DL et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007; 83: 1162-1168
    CrossrefPubMedSearch in Google Scholar
  • 20 Villanueva A, Hoshida Y, Battiston C et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011; 140: 1501-1512 e1502
    CrossrefPubMedSearch in Google Scholar
  • 21 Worns MA, Weinmann A, Pfingst K et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43: 489-495
    CrossrefPubMedSearch in Google Scholar
  • 22 Yau T, Yao TJ, Chan P et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist 2011; 16: 1270-1279
    CrossrefPubMedSearch in Google Scholar